Breast cancer treatment bonanza

Two meta-analyses provide evidence that aromatase inhibitors and bisphosphonates improve breast cancer survival in post-menopausal women, and the therapies complement each other.

Aromatase inhibitors reduce breast cancer recurrence rates while on treatment by about 30% compared with tamoxifen, an analysis of nearly 32,000 post-menopausal women with oestrogen-positive early breast cancer, shows.

And the benefits